Press Releases

« Back
Printer Friendly Version View printer-friendly version
Iovance Biotherapeutics to Participate in Upcoming Conferences in May

SAN CARLOS, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to participate in the following conferences in May:

  • NYAS Frontiers in Cancer Immunotherapy in New York, May 14-15, 2019

            Panel Presentation: Will CAR-T Cell Therapies, Bispecific Antibodies, or TILs Be More Beneficial for Solid Tumors?
            Session: Session 4, Breakout Track B
            Location: The New York Academy of Sciences
            Date/time: Wednesday, May 15, at 1:00 p.m. EDT

  • Oppenheimer Oncology Insight Summit in New York, May 16, 2019

            Location: InterContinental New York Barclay Hotel

  • AACR Bladder Cancer: Transforming the Field Conference in Denver, May 18-21, 2019

            Poster Presentation: Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from advanced bladder cancer for adoptive immunotherapy
            Authors: Qiang John Li et al.
            Session Type: Poster Session A
            Abstract Number: A05
            Location: Grand Hyatt Denver
            Date/Time: Sunday, May 19, from 12:30 p.m. - 3:00 p.m. MDT

  • 20th Annual B. Riley FBR Investor Conference in Beverly Hills, CA, May 22-23, 2019

            Location: The Beverly Hilton Hotel
            Date/Time: Thursday, May 23, at 9:00 a.m. PDT
            A live and archived webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics’ website at http://ir.iovance.com.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics intends to commercialize lifileucel, an autologous cell therapy product using TIL technology that amplifies the body’s own immune response to eradicate solid tumors or attack blood cancers. The company is currently conducting the pivotal study innovaTIL-01 in patients with metastatic melanoma. In addition, the company’s TIL therapies are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including cervical, head and neck, and non-small cell lung cancer. For more information, please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”). We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “likely,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. The forward-looking statements include, but are not limited to, risks and uncertainties relating to the success, timing, projected enrollment, manufacturing capabilities, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, such as statements regarding the timing of initiation and completion of these trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates; the strength of Company’s product pipeline; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s manufacturing, license or development agreements; the time of and our ability to commercialize our product candidates; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements.  Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the FDA may not agree with the Company’s interpretation of the results of its clinical trials; later developments with the FDA that may be inconsistent with already completed FDA meetings; the preliminary clinical results, including efficacy and safety results, from ongoing Phase 2 studies may not be reflected in the final analyses of these trials, including new cohorts within these trials, and may not be supportive of product approval; the FDA or other regulatory authorities may potentially delay the timing of their approval of, or other action with respect to, the Company’s product candidates (specifically, the Company’s description of FDA interactions are subject to FDA’s interpretation, as well as FDA’s authority to request new or additional information); the Company’s ability to address FDA or other regulatory authority requirements relating to its clinical programs and registrational plans, such requirements including, but not limited to, clinical and safety requirements as well as manufacturing and control requirements; risks related to the Company’s accelerated FDA review designations, including the Company’s ability to maintain and benefit from such designations; and the ability of the Company to manufacture its therapies using third party manufacturers.  A further list and description of the Company’s risks, uncertainties and other factors can be found in the Company’s most recent Annual Report on Form 10-K and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.iovance.com. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Contacts: 
Annie Chang
Solebury Trout
646-378-2972
achang@troutgroup.com

Chad Rubin
Solebury Trout
646-378-2947
crubin@troutgroup.com

Media Relations Contact:
Rich Allan
Solebury Trout
646-378-2958
rallan@troutgroup.com

Iovance.jpg

Iovance Biotherapeutics, Inc.